Slingshot members are tracking this event:
ZIOPHARM (ZIOP) to finish Phase 1 study of Ad-RTS-hIL-12 with Veledimex in Subjects With Glioblastoma or Malignant Glioma in December 2016
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Nov 17, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 1 Study, Ad-rts-hil-12, Veledimex, Glioblastoma, Glioma, Open-label, Brain Cancer